Cargando…

2022. Modeling Improved Patient Management and Hospital Savings with SeptiCyte LAB in the Diagnosis of Sepsis at ICU Admission

BACKGROUND: The ability to accurately diagnose sepsis at ICU admission is key to effective clinical management, patient safety, and efficient hospital resource utilization. Most tests used for sepsis diagnosis, including pathogen detection and host-based biomarker approaches, are lacking in either s...

Descripción completa

Detalles Bibliográficos
Autor principal: Mchugh, Leo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252755/
http://dx.doi.org/10.1093/ofid/ofy210.1678
_version_ 1783373337113657344
author Mchugh, Leo
author_facet Mchugh, Leo
author_sort Mchugh, Leo
collection PubMed
description BACKGROUND: The ability to accurately diagnose sepsis at ICU admission is key to effective clinical management, patient safety, and efficient hospital resource utilization. Most tests used for sepsis diagnosis, including pathogen detection and host-based biomarker approaches, are lacking in either sensitivity or specificity, resulting in a clinical assumption of sepsis, patient overtreatment with antimicrobials, and hospital or ICU admission as a precaution. SeptiCyte LAB is the only FDA-cleared test that analyzes the patient’s own host transcriptional response in systemically inflamed patients, to discriminate between infectious and non-infectious underlying causes. METHODS: The SeptiCyte LAB test was validated in a multi-site prospective trial in the ICU (N = 447). Test performance and length of stay in both the ICU and hospital were recorded. Length of stay associated with initial diagnoses was directly recorded, and a model was created in which costs/savings due to the added deployment of the SeptiCyte LAB assay, in comparison to the standard of care, was projected. Assumptions for the timing of antimicrobial de-escalation and hospital stay costs were drawn from published literature. Assumptions for changes in clinical management were based on required minimum negative and positive predictive values. RESULTS: The estimated savings due to reduced length of stay per patient, as a consequence of the information generated by SeptiCyte LAB was found to be approximately $1,600 in the ICU, and an estimated $900 on the ward. Matched procalcitonin results from the same trial and exclusively used for de-escalation as specified by the manufacturer resulted in per-patient savings of $80. CONCLUSION: Modeling of a rapid and accurate diagnosis sepsis diagnostic (SeptiCyte LAB) at ICU admission projects significant savings and improvements in patient management. DISCLOSURES: L. Mchugh, Immunexpress: Employee, Salary.
format Online
Article
Text
id pubmed-6252755
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62527552018-11-28 2022. Modeling Improved Patient Management and Hospital Savings with SeptiCyte LAB in the Diagnosis of Sepsis at ICU Admission Mchugh, Leo Open Forum Infect Dis Abstracts BACKGROUND: The ability to accurately diagnose sepsis at ICU admission is key to effective clinical management, patient safety, and efficient hospital resource utilization. Most tests used for sepsis diagnosis, including pathogen detection and host-based biomarker approaches, are lacking in either sensitivity or specificity, resulting in a clinical assumption of sepsis, patient overtreatment with antimicrobials, and hospital or ICU admission as a precaution. SeptiCyte LAB is the only FDA-cleared test that analyzes the patient’s own host transcriptional response in systemically inflamed patients, to discriminate between infectious and non-infectious underlying causes. METHODS: The SeptiCyte LAB test was validated in a multi-site prospective trial in the ICU (N = 447). Test performance and length of stay in both the ICU and hospital were recorded. Length of stay associated with initial diagnoses was directly recorded, and a model was created in which costs/savings due to the added deployment of the SeptiCyte LAB assay, in comparison to the standard of care, was projected. Assumptions for the timing of antimicrobial de-escalation and hospital stay costs were drawn from published literature. Assumptions for changes in clinical management were based on required minimum negative and positive predictive values. RESULTS: The estimated savings due to reduced length of stay per patient, as a consequence of the information generated by SeptiCyte LAB was found to be approximately $1,600 in the ICU, and an estimated $900 on the ward. Matched procalcitonin results from the same trial and exclusively used for de-escalation as specified by the manufacturer resulted in per-patient savings of $80. CONCLUSION: Modeling of a rapid and accurate diagnosis sepsis diagnostic (SeptiCyte LAB) at ICU admission projects significant savings and improvements in patient management. DISCLOSURES: L. Mchugh, Immunexpress: Employee, Salary. Oxford University Press 2018-11-26 /pmc/articles/PMC6252755/ http://dx.doi.org/10.1093/ofid/ofy210.1678 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Mchugh, Leo
2022. Modeling Improved Patient Management and Hospital Savings with SeptiCyte LAB in the Diagnosis of Sepsis at ICU Admission
title 2022. Modeling Improved Patient Management and Hospital Savings with SeptiCyte LAB in the Diagnosis of Sepsis at ICU Admission
title_full 2022. Modeling Improved Patient Management and Hospital Savings with SeptiCyte LAB in the Diagnosis of Sepsis at ICU Admission
title_fullStr 2022. Modeling Improved Patient Management and Hospital Savings with SeptiCyte LAB in the Diagnosis of Sepsis at ICU Admission
title_full_unstemmed 2022. Modeling Improved Patient Management and Hospital Savings with SeptiCyte LAB in the Diagnosis of Sepsis at ICU Admission
title_short 2022. Modeling Improved Patient Management and Hospital Savings with SeptiCyte LAB in the Diagnosis of Sepsis at ICU Admission
title_sort 2022. modeling improved patient management and hospital savings with septicyte lab in the diagnosis of sepsis at icu admission
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252755/
http://dx.doi.org/10.1093/ofid/ofy210.1678
work_keys_str_mv AT mchughleo 2022modelingimprovedpatientmanagementandhospitalsavingswithsepticytelabinthediagnosisofsepsisaticuadmission